DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

Phase 2

Completed

Conditions: PCSK9
Lipoprotein Metabolism
Proteomics

Interventions: Drug: DHA-rich fish oil
Drug: EPA-rich fish oil

First Posted Date: 2015-08-03

Last Posted Date: 2021-07-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 44

Registration Number: NCT02514070

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Drug: Fludarabine

First Posted Date: 2015-08-03

Last Posted Date: 2023-03-24

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 29

Registration Number: NCT02514083

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Hereditary Parkinson s Disease Natural History Protocol

Completed

Conditions: Parkinson Disease 6, Early-Onset
Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human
Parkinson Disease Autosomal Recessive, Early Onset

First Posted Date: 2015-07-29

Last Posted Date: 2024-10-26

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 31

Registration Number: NCT02511015

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Effect of Fasting on the Asthma Inflammasome

Completed

Conditions: Asthma

First Posted Date: 2015-06-15

Last Posted Date: 2021-02-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 19

Registration Number: NCT02471300

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Allogeneic HSCT
Drug: Fludarabine
Drug: Melphalan
Drug: Bortezomib
Drug: Placebo
Drug: Ixazomib

First Posted Date: 2015-05-12

Last Posted Date: 2023-01-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 57

Registration Number: NCT02440464

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Texas /MD Anderson CRC, Houston, Texas, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 12 locations

dbGaP Protocol: Genetic Variants Associated With Pentalogy of Cantrell

Completed

Conditions: Pentalogy of Cantrell

First Posted Date: 2015-04-30

Last Posted Date: 2019-03-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 3280

Registration Number: NCT02430376

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Genome Transplant Dynamics

Recruiting

Conditions: Thoracic Organ Transplantation

First Posted Date: 2015-04-22

Last Posted Date: 2025-05-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 991

Registration Number: NCT02423070

Locations: 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

and more 3 locations

Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)

Recruiting

Conditions: Healthy Subjects

First Posted Date: 2015-04-16

Last Posted Date: 2025-05-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 215

Registration Number: NCT02417714

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids

Phase 1

Terminated

Conditions: Graft-Versus-Host Disease

Interventions: Biological: MSC

First Posted Date: 2015-03-05

Last Posted Date: 2019-05-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1

Registration Number: NCT02379442

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Phase 3

Completed

Conditions: Acute Leukemia
Myelodysplasia

Interventions: Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft
Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate
Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide
Drug: Tacrolimus
Drug: Cyclophosphamide
Drug: Methotrexate

First Posted Date: 2015-01-26

Last Posted Date: 2023-03-07

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 346

Registration Number: NCT02345850

Locations: 🇺🇸
Johns Hopkins/SKCCC, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute/Brigham & Women's, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy